Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lachmann

Showing results (331-340 of 426) with videos related to

Pageof 43
Sort By:
British Journal of Haematology|June 17, 2014
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimensShameem Mahmood, Christopher P Venner, Sajitha Sachchithanantham, et al.
Leukemia|July 17, 2014
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosisC P Venner, J D Gillmore, S Sachchithanantham, et al.
European Journal of Haematology|January 18, 2021
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UKFaye A Sharpley, Richa Manwani, Aviva Petrie, et al.
Kidney International|July 22, 2017
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factorTamer Rezk, Helen J Lachmann, Marianna Fontana, et al.
British Journal of Haematology|August 8, 2019
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathyRicha Manwani, Shameem Mahmood, Sajitha Sachchithanantham, et al.
British Journal of Haematology|March 14, 2013
Systemic amyloidosis in England: an epidemiological studyJennifer H Pinney, Colette J Smith, Jessi B Taube, et al.
Clinical and Experimental Rheumatology|July 20, 2023
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndromeAnna M Gerritsma, Diana Sutera, Luca Cantarini, et al.
The New England Journal of Medicine|June 8, 2007
Eprodisate for the treatment of renal disease in AA amyloidosisLaura M Dember, Philip N Hawkins, Bouke P C Hazenberg, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 6, 2018
Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosisTamer Rezk, Janet A Gilbertson, Dorota Rowczenio, et al.
Frontiers in Immunology|November 23, 2017
Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center ExperienceDorota M Rowczenio, Sónia Melo Gomes, Juan I Aróstegui, et al.
Pageof 43

Showing results (331-340 of 426) with videos related to

Sort By:
Pageof 43
British Journal of Haematology|June 17, 2014
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimensShameem Mahmood, Christopher P Venner, Sajitha Sachchithanantham, et al.
Leukemia|July 17, 2014
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosisC P Venner, J D Gillmore, S Sachchithanantham, et al.
European Journal of Haematology|January 18, 2021
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UKFaye A Sharpley, Richa Manwani, Aviva Petrie, et al.
Kidney International|July 22, 2017
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factorTamer Rezk, Helen J Lachmann, Marianna Fontana, et al.
British Journal of Haematology|August 8, 2019
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathyRicha Manwani, Shameem Mahmood, Sajitha Sachchithanantham, et al.
British Journal of Haematology|March 14, 2013
Systemic amyloidosis in England: an epidemiological studyJennifer H Pinney, Colette J Smith, Jessi B Taube, et al.
Clinical and Experimental Rheumatology|July 20, 2023
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndromeAnna M Gerritsma, Diana Sutera, Luca Cantarini, et al.
The New England Journal of Medicine|June 8, 2007
Eprodisate for the treatment of renal disease in AA amyloidosisLaura M Dember, Philip N Hawkins, Bouke P C Hazenberg, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 6, 2018
Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosisTamer Rezk, Janet A Gilbertson, Dorota Rowczenio, et al.
Frontiers in Immunology|November 23, 2017
Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center ExperienceDorota M Rowczenio, Sónia Melo Gomes, Juan I Aróstegui, et al.
Pageof 43